This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ding, V. D. H. Articles by Smith, R. G. Search for Related Content PubMed PubMed Citation Articles by Ding, V. D. H. Articles by Smith, R. G.

Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway

Department of Biochemistry and Physiology, Department of Laboratory Animal Resources, Merck Research Laboratories, Rahway, New Jersey 07065; and Department of Medicine, St. Luke’s/Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University New York, New York 10019

Address all correspondence and requests for reprints to: Dr. V. Ding, Department of Molecular Endocrinology, Merck Research Laboratories (RY80W-243), P.O. Box 2000, Rahway, New Jersey 07065. E-mail: victor-ding{at}merck.com

Estradiol (E₂) and 5-androstan-3,17ß-diol (3-diol) have been implicated in prostate hyperplasia in man and dogs, but neither of these steroids bind to androgen receptors (ARs). Recently, we reported that E₂ and 3-diol stimulated generation of intracellular cAMP via binding to a complex of sex hormone-binding globulin (SHBG) and its receptor (R_SHBG) on prostate cells. We speculated that this pathway, involving steroids normally found in the prostate, was involved in the indirect activation of ARs. Using the dog as a model to test this hypothesis in normal prostate, we investigated whether E₂, 3-diol, and SHBG stimulated the production of the androgen-responsive protein, arginine esterase (AE), the canine equivalent of human prostate-specific antigen. In cultured dog prostate tissue preincubated with SHBG, E₂ and 3-diol stimulated AE activity. These effects were blocked by hydroxyflutamide, an AR antagonist, and by 2-methoxyestradiol, a competitive inhibitor of E₂ and 3-diol binding to SHBG. In the absence of exogenous steroids and SHBG, AE also was significantly increased by treatment with forskolin or 8-Bromoadenosine-cAMP. These observations support the hypothesis that in normal prostate, E₂ and 3-diol can amplify or substitute for androgens, with regard to activation of the AR via the R_SHBG by a signal transduction pathway involving cAMP. Because both E₂ and 3-diol are involved in the pathogenesis of benign prostatic hyperplasia in dogs and implicated in benign prostatic hyperplasia in man, antagonism of the prostatic SHBG pathway may offer a novel and attractive therapeutic target.

This article has been cited by other articles:

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				B. E. LeRoy, M. V. P. Nadella, R. E. Toribio, I. Leav, and T. J. Rosol Canine Prostate Carcinomas Express Markers of Urothelial and Prostatic Differentiation Vet. Pathol., March 1, 2004; 41(2): 131 - 140. [Abstract] [Full Text] [PDF]

				J. L. Mohler, C. W. Gregory, O. H. Ford III, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson, and F. S. French The Androgen Axis in Recurrent Prostate Cancer Clin. Cancer Res., January 15, 2004; 10(2): 440 - 448. [Abstract] [Full Text] [PDF]

				R. M. LOSEL, E. FALKENSTEIN, M. FEURING, A. SCHULTZ, H.-C. TILLMANN, K. ROSSOL-HASEROTH, and M. WEHLING Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev, July 1, 2003; 83(3): 965 - 1016. [Abstract] [Full Text] [PDF]

				J. D. Wilson, R. J. Auchus, M. W. Leihy, O. L. Guryev, R. W. Estabrook, S. M. Osborn, G. Shaw, and M. B. Renfree 5{alpha}-Androstane-3{alpha},17{beta}-Diol Is Formed in Tammar Wallaby Pouch Young Testes by a Pathway Involving 5{alpha}-Pregnane-3{alpha},17{alpha}-Diol-20-One as a Key Intermediate Endocrinology, February 1, 2003; 144(2): 575 - 580. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions Mol. Endocrinol., October 1, 2002; 16(10): 2181 - 2187. [Abstract] [Full Text] [PDF]

				D. J. Hryb, A. M. Nakhla, S. M. Kahn, J. St. George, N. C. Levy, N. A. Romas, and W. Rosner Sex Hormone-binding Globulin in the Human Prostate Is Locally Synthesized and May Act as an Autocrine/Paracrine Effector J. Biol. Chem., July 12, 2002; 277(29): 26618 - 26622. [Abstract] [Full Text] [PDF]

				S. Monti, F. Di Silverio, R. Iraci, C. Martini, S. Lanzara, P. Falasca, M. Poggi, A. Stigliano, F. Sciarra, and V. Toscano Regional Variations of Insulin-Like Growth Factor I (IGF-I), IGF-II, and Receptor Type 1 in Benign Prostatic Hyperplasia Tissue and Their Correlation with Intraprostatic Androgens J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1700 - 1706. [Abstract] [Full Text]

				E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling Multiple Actions of Steroid Hormones---A Focus on Rapid, Nongenomic Effects Pharmacol. Rev., December 1, 2000; 52(4): 513 - 556. [Abstract] [Full Text] [PDF]

				D. M. Selva, O. M. Tirado, N. Toran, C. A. Suarez-Quian, J. Reventos, and F. Munell Meiotic Arrest and Germ Cell Apoptosis in Androgen-Binding Protein Transgenic Mice Endocrinology, March 1, 2000; 141(3): 1168 - 1177. [Abstract] [Full Text] [PDF]

				W. P. M. benten, M. Lieberherr, G. Giese, C. Wrehlke, O. Stamm, C. E. Sekeris, H. Mossmann, and F. Wunderlich Functional testosterone receptors in plasma membranes of T cells FASEB J, January 1, 1999; 13(1): 123 - 133. [Abstract] [Full Text]

				G. Shaw, M. B. Renfree, M. W. Leihy, C. H. L. Shackleton, E. Roitman, and J. D. Wilson Prostate formation in a marsupial is mediated by the testicular androgen 5alpha -androstane-3alpha ,17beta -diol PNAS, October 24, 2000; 97(22): 12256 - 12259. [Abstract] [Full Text] [PDF]